keyword
MENU ▼
Read by QxMD icon Read
search

hyperthermic intraperitoneal chemotherapy

keyword
https://www.readbyqxmd.com/read/28812384/identification-of-risk-factors-associated-with-postoperative-acute-kidney-injury-after-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy-a-retrospective-study
#1
Juan P Cata, Acsa M Zavala, Antoinette Van Meter, Uduak U Williams, Jose Soliz, Mike Hernandez, Pascal Owusu-Agyemang
BACKGROUND: Acute kidney injury (AKI) is a postoperative complication associated with significant morbidity and mortality. The incidence and risks factors for AKI after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) have not been fully studied. The purpose of this study was to identify perioperative risk factors predictive of AKI after CRS-HIPEC. METHODS: This retrospective study collected demographic, tumor-related, intraoperative and postoperative data from 475 patients who underwent CRS-HIPECs...
August 16, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28812240/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-pseudomyxoma-peritonei-and-appendix-tumours-in-elderly-patients-is-it-justified
#2
V López-López, P A Cascales-Campos, E Gil, J Arevalo, A Gonzalez, J Gil, F C Muñoz-Casares, J T Melero, P Barrios, R Morales, I Ramos, G Ortega, B Camps, L González-Bayón, P Bretcha-Boix, J Farré-Alegre, S González-Moreno, P Parrilla
BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei and appendix tumours are widespread in the world. It is unclear what should be the attitude in elderly patients. METHODS: This retrospective multicenter study collected the database from ten Spanish centers from Spanish Group of Peritoneal Cancer Surgery. The study period was between November 2002 and March 2014. Seventeen patients with age greater than or equal to 75 years with peritoneal carcinomatosis from pseudomyxoma peritonei and appendix tumours met the selection criteria for the study...
August 10, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28810883/treatment-of-localized-gastric-and-gastroesophageal-adenocarcinoma-the-role-of-accurate-staging-and-preoperative-therapy
#3
REVIEW
Brian Badgwell, Prajnan Das, Jaffer Ajani
Gastric cancer is the third most common cause of cancer death worldwide, although it is not in the top 10 causes of cancer death in Northern America. Due to clear differences in incidence, screening, risk factors, tumor biology, and treatment between gastric cancers from Eastern and Western countries, our treatment is primarily guided by trials from Western countries. Patients undergo an extensive staging evaluation including high-quality CT imaging, endoscopic ultrasound, and diagnostic laparoscopy with peritoneal washings for cytology...
August 15, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28808875/ssat-state-of-the-art-conference-current-surgical-management-of-gastric-tumors
#4
Jeffrey A Norton, Teresa Kim, Joseph Kim, Martin D McCarter, Kaitlyn J Kelly, Joyce Wong, Jason K Sicklick
INTRODUCTION: The current era of gastric surgery is marked by low morbidity and mortality rates, innovative strategies to approach resections with a minimally invasive fashion or hyperthermic intraperitoneal chemotherapy (HIPEC), as well as improved understanding of the biology of sporadic and hereditary stromal, neuroendocrine, and epithelial malignancies. METHODS: In 2017, the Society for Surgery of the Alimentary Tract convened a State-of-the-Art Conference on Current Surgical Management of Gastric Tumors with both international experts and emerging leaders in the field of gastric surgery...
August 14, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/28807243/is-hyperthermic-intraperitoneal-chemotherapy-hipec-safe-for-healthcare-workers
#5
REVIEW
Simon Rodier, Guillaume Saint-Lorant, Jean-Marc Guilloit, Agnès Palix, Fabienne Divanon, François Sichel, Raphaël Delépée
BACKGROUND: During hyperthermic intraperitoneal chemotherapy (HIPEC), caregivers are exposed by different routes to cytotoxic drugs. This review proposes an overview of the safety of HIPEC by assessing existing data on protection procedures, biological and non-biological samples. Based on these data, relevant good practices, eventual irrelevant overprotection procedures and missing data to implement adapted protections are highlighted. MATERIALS AND METHODS: Data were extracted from a systematic review of literature from 1980 till 2016: number and type of surgical procedure, healthcare professionals present, protective equipment, samples, pre-analytical method and analytical method...
September 2017: Surgical Oncology
https://www.readbyqxmd.com/read/28799004/phase-ii-trial-of-laparoscopic-hyperthermic-intraperitoneal-chemoperfusion-for-peritoneal-carcinomatosis-or-positive-peritoneal-cytology-in-patients-with-gastric-adenocarcinoma
#6
Brian Badgwell, Mariela Blum, Prajnan Das, Jeannelyn Estrella, Xuemei Wang, Linus Ho, Keith Fournier, Richard Royal, Paul Mansfield, Jaffer Ajani
PURPOSE: The aim of this phase II study was to perform neoadjuvant hyperthermic intraperitoneal chemoperfusion (HIPEC) via a minimally invasive approach without cytoreduction for patients with gastric cancer and positive peritoneal cytology or low-volume peritoneal carcinomatosis. METHODS: Patients with gastric or gastroesophageal adenocarcinoma and positive peritoneal cytology or radiologically occult peritoneal carcinomatosis after systemic chemotherapy received laparoscopic HIPEC with mitomycin C 30 mg and cisplatin 200 mg...
August 10, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28797997/hepatocellular-carcinoma-peritoneal-metastasis-role-of-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-hipec
#7
John Spiliotis, Georgios Nikolaou, Nikolaos Kopanakis, Dimitra Vassiliadou, Alexios Terra, Elias Efstathiou
INTRODUCTION: Peritoneal dissemination of hepatocellular carcinoma (HCC) is a rare presentation with an incidence of 2-6%. The most common cause of peritoneal deposits is a ruptured HCC that results in tumor spillage into the peritoneal cavity. The overall incidence of spontaneous ruptures of HCC ranges from 5 to 15% and carries a high mortality rate of up to 50%. Other factors influencing peritoneal dissemination are the lymph node metastasis and the direct diaphragmatic invasion and there is no significant association with past history of FNAB, or percutaneous RFA or ethanol injection and lung or adrenal metastasis...
May 2017: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28770289/diagnostic-value-of-contrast-enhanced-ct-combined-with-18-fdg-pet-in-patients-selected-for-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-hipec
#8
Antonio Sommariva, Laura Evangelista, Giovanna Pintacuda, Anna Rita Cervino, Gaetano Ramondo, Carlo Riccardo Rossi
PURPOSE: Aim of the study is to assess the reliability and correlation with surgical peritoneal cancer index (PCI) of combined PET/CT and ceCT scans (PET/ceCT) performed in a session in patients with peritoneal carcinomatosis candidates for cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: We retrospectively analyzed data collected from 27 patients with different types of peritoneal carcinomatosis candidates to CS + HIPEC who underwent FDG PET/ceCT in a single session...
August 2, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28743181/feasibility-and-safety-of-hyperthermic-intraperitoneal-chemotherapy-using-5-fluorouracil-combined-with-cisplatin-and-mitomycin-c-in-patients-undergoing-gastrectomy-for-advanced-gastric-cancer
#9
Satoshi Murata, Hiroshi Yamamoto, Hiroyuki Naitoh, Tsuyoshi Yamaguchi, Sachiko Kaida, Tomoharu Shimizu, Hisanori Shiomi, Shigeyuki Naka, Tohru Tani, Masaji Tani
BACKGROUND AND OBJECTIVES: We conducted a dose-finding study for 5-fluorouracil (5-FU) administered with cisplatin (CDDP) and mitomycin C (MMC) to find an improved regimen for hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer (GC). METHODS: The appropriate HIPEC regimen previously determined in vitro was 5-FU (200 µg/mL), MMC (2 µg/mL), and CDDP (10 µg/mL) at hyperthermic conditions (42°C) for 30 min. This was a clinical study to determine the recommended dose of 5-FU in combination with MMC and CDDP at 42°C for 30 min and to evaluate HIPEC safety in patients at high risk of developing peritoneal metastases following GC surgery...
July 25, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28737098/abdominal-wall-morbidity-following-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#10
F Struller, I Koenigsrainer, P Horvath, A Koenigsrainer, S Beckert
BACKGROUND: Incisional hernia formation has been reported as high as 20% within 1 year following midline laparotomy. Since hyperthermic intraperitoneal chemotherapy is likely to impair wound healing, we sought to investigate the incidence of incisional hernia formation and abdominal wall rupture following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. METHODS: Consecutive patients with radiographic evidence of peritoneal metastases were scheduled for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at the Comprehensive Cancer Center, University Hospital Tuebingen, Germany...
March 1, 2017: Scandinavian Journal of Surgery: SJS
https://www.readbyqxmd.com/read/28736644/overall-and-disease-free-survival-in-patients-treated-with-crs-hipec-with-cisplatin-and-paclitaxel-for-gastric-cancer-with-peritoneal-carcinomatosis
#11
Paola Fugazzola, Federico Coccolini, Giulia Montori, Marco Ceresoli, Paolo Baggi, Antonio Costanzo, Matteo Tomasoni, Francesco Gregis, Silvia Nozza, Luca Ansaloni
BACKGROUND: Our experience regarding cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was reviewed in terms of overall survival (OS) and disease-free survival (DFS) in patients with synchronous peritoneal carcinomatosis (SPC) and metachronous peritoneal carcinomatosis (MPC) from gastric cancer (GC). METHODS: An analysis of prospectively collected data about patients who underwent CRS and HIPEC from July 2011 to July 2016 was carried out...
June 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28730790/perioperative-systemic-chemotherapy-for-peritoneal-mucinous-appendiceal-carcinomas-treated-with-cytoreductive-surgery-hipec
#12
John Spiliotis, Nikolaos Kopanakis, Elias Efstathiou, Dimitra Vassiliadou, Orestis Argiriou, Athanassios Rogdakis, Christos Valavanis
PURPOSE: To identify the role of systemic chemotherapy in the management of appendiceal malignancies. METHODS: Over a 10-year period (2005 -2014), 52 patients with appendiceal neoplasms were treated at our Peritoneal Surface Malignancy Unit [14 (26.9%) disseminated peritoneal adenomucinosis (DPAM), 30 (57.7%) peritoneal mucinous carcinomatosis of appendiceal origin (PMCA) and 8 (15.4%) PMCA-I]. All patients (100%) underwent cytoreductive surgery (CRS) & hyperthermic intraperitoneal chemotherapy (HIPEC), while 20 (38...
May 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28721098/patient-selection-for-cytoreductive-surgery-and-hipec-for-the-treatment-of-peritoneal-metastases-from-colorectal-cancer
#13
REVIEW
Geert A Simkens, Koen P Rovers, Simon W Nienhuijs, Ignace H de Hingh
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a viable option for selected patients with peritoneal metastases (PM) from colorectal origin, resulting in long-term survival and even cure in some cases. However, adequate patient selection for this treatment is currently one of the major challenges. The aim of this review is to provide a comprehensive overview of clinically relevant factors associated with overall survival. This may help to guide clinicians through the complex interplay of patient, tumor, and treatment characteristics to adequately select patients who benefit the most from this extensive surgical treatment...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28719887/anesthetic-management-of-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-crs-hipec-the-importance-of-hydro-electrolytic-and-acid-basic-control
#14
Fabrício Tavares Mendonça, Marília Moreira Guimarães, Sérgio Honorato de Matos, Rúbia Garcia Dusi
JUSTIFICATION AND OBJECTIVES: Patients affected by gynecological or gastrointestinal tract neoplasms that evolve to peritoneal carcinomatosis experience a significant drop in their quality of life, high morbidity and short survival times with currently available chemotherapeutic schemes. The surgical treatment based on cytoreduction and the employment of hyperthermic intraperitoneal chemotherapy in the intra-operative period is a true challenge to anesthesiologist. CASE REPORT: A 67 years old patient diagnosed with mucinous adenocarcinoma of the Appendix associated with mucinous carcinomatosis, was submitted to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), under general anesthesia and epidural block...
2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28715968/applications-of-hyperthermic-intraperitoneal-chemotherapy-for-metastatic-colorectal-cancer
#15
Matthias Hornung, Jens M Werner, Hans J Schlitt
Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) plays a pivotal role in the current treatment of peritoneal carcinomatosis (PC) from colorectal cancer (CRC). Since the first demonstration, benefits for patients and especially an increase in survival have been described. In recent years, feasibility, efficacy and safety of HIPEC have been improved and progress has been made in understanding its oncological mechanism. Areas covered: In this article, leading publications have been reviewed including clinical trials to describe the clinical presentation of PC due to CRC and present recent evidence of the CRS/HIPEC procedure...
July 25, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28709979/reconstruction-after-ureteral-resection-during-hipec-surgery-re-implantation-with-uretero-neocystostomy-seems-safer-than-end-to-end-anastomosis
#16
U Pinar, J-F Tremblay, G Passot, M Dazza, O Glehen, J-J Tuech, M Pocard
INTRODUCTION: Resection of the pelvic ureter may be necessary in cytoreductive surgery for peritoneal carcinomatosis in combination with hyperthermic intraperitoneal chemotherapy (HIPEC). As the morbidity for cytoreductive surgery with HIPEC has decreased, expert teams have begun to perform increasingly complex surgical procedures associated with HIPEC, including pelvic reconstructions. After ureteral resection, two types of reconstruction are possible: uretero-ureteral end-to-end anastomosis and uretero-vesical re-implantation or uretero-neocystostomy (the so-called psoas hitch technique)...
July 11, 2017: Journal of Visceral Surgery
https://www.readbyqxmd.com/read/28705789/treatment-of-peritoneal-dissemination-in-stomach-cancer-patients-with-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-hipec-rationale-and-design-of-the-periscope-study
#17
Rosa T van der Kaaij, Hidde Jw Braam, Henk Boot, Maartje Los, Annemieke Cats, Cecile Grootscholten, Jan Hm Schellens, Arend Gj Aalbers, Alwin Dr Huitema, Catherijne Aj Knibbe, Djamila Boerma, Marinus J Wiezer, Bert van Ramshorst, Johanna W van Sandick
BACKGROUND: Patients with gastric cancer and peritoneal carcinomatosis have a very poor prognosis; median survival is 3 to 4 months. Palliative systemic chemotherapy is currently the only treatment available in the Netherlands. Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) has an established role in the treatment of peritoneal carcinomatosis originating from colorectal cancer, appendiceal cancer, and pseudomyxoma peritonei; its role in gastric cancer is uncertain. Currently, there is no consensus on the choice of chemotherapeutic agents used in HIPEC for gastric cancer...
July 13, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28695617/morbidity-and-mortality-of-elderly-patients-following-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-hipec
#18
Evelyn Y T Wong, Grace H C Tan, Claramae S L Chia, Mrinal Kumar, Khee Chee Soo, Melissa C C Teo
AIM: Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is known to improve survival in selected patients with peritoneal metastasis. However, there is limited data supporting the role of CRS and HIPEC in elderly patients (≥65 years old). METHODS: A retrospective review of a prospectively maintained database of patients who underwent CRS-HIPEC between April 2001 and July 2015 from a single institution was performed. Patients were divided into two groups non-elderly (<65 years old), and elderly (≥65 years old)...
July 11, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28695394/cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-for-moderately-and-poorly-differentiated-appendiceal-adenocarcinoma-survival-outcomes-and-patient-selection
#19
Travis E Grotz, Michael J Overman, Cathy Eng, Kanwal P Raghav, Richard E Royal, Paul F Mansfield, Gary N Mann, Kristen A Robinson, Karen A Beaty, Safia Rafeeq, Aurelio Matamoros, Melissa W Taggart, Keith F Fournier
BACKGROUND: Moderately and poorly differentiated adenocarcinoma of the appendix represents an aggressive histological variant with a high risk of recurrence and death. METHODS: Overall, 178 patients with moderately and poorly differentiated appendiceal adenocarcinoma were identified from a prospective database. Clinical, pathologic, and treatment factors were analyzed for outcomes. RESULTS: Diagnostic laparoscopy (DL) identified radiographic occult peritoneal metastasis in 25 (42%) patients...
July 10, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28689443/does-having-a-gastrectomy-delay-time-to-feeding-and-prolong-hospital-stay-in-patients-undergoing-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#20
Nicholas Brian Shannon, Grace Hwei Ching Tan, Claramae Shulyn Chia, Khee Chee Soo, Melissa Ching Teo
AIM: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is routinely used to treat selected patients with peritoneal carcinomatosis, but can be associated with prolonged hospital stay, significant morbidity and mortality. Our objective was to assess whether patients undergoing gastrectomy as part of CRS/HIPEC were at increased risk of delayed feeding time and prolonged hospital stay. METHODS: Two hundred and fourteen consecutive patients with peritoneal carcinomatosis treated with CRS/HIPEC between 2001 and 2016 were stratified by whether CRS included gastrectomy (n = 19, 9%) and compared...
July 26, 2017: International Journal of Hyperthermia
keyword
keyword
84002
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"